HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Blood test may help personalize chemo for head and neck cancer patients
Disease control TerminatedThis study tests whether a simple blood test that measures tumor DNA can help doctors decide when to add short bursts of chemotherapy to standard immunotherapy for people with head and neck cancer that has returned or spread. The goal is to see if this personalized approach works…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated May 01, 2026 15:29 UTC
-
Voice-Saving cancer trial: which treatment keeps the larynx working best?
Disease control OngoingThis study tests two ways to treat advanced throat cancer while trying to avoid removing the voice box (larynx). One group gets chemotherapy first, then radiation. The other gets radiation plus a different chemo drug at the same time. The goal is to see which approach better keep…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Groupe Oncologie Radiotherapie Tete et Cou • Aim: Disease control
Last updated May 01, 2026 15:28 UTC
-
Immune-Boosting cocktail aims to shrink Head/Neck tumors before surgery
Disease control OngoingThis early-phase study tests two experimental drugs (LVGN7409 and LVGN3616) given together before surgery for people with HPV-negative head and neck cancer. The goal is to see if this combination is safe and can activate the immune system to attack the tumor. About 27 adults will…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated May 01, 2026 15:28 UTC
-
New drug targets tough cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called LY4101174 in people with advanced solid tumors that have come back or spread. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to check safety, find the right dose, and see if it shri…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 01, 2026 15:27 UTC
-
Cancer combo trial pulled before it began
Disease control TerminatedThis study was designed to test the safety and effectiveness of combining two drugs (TTI-101 and pembrolizumab) for people with head and neck cancer that had spread or come back. It planned to enroll adults whose cancer could not be cured with standard treatments. However, the st…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 01, 2026 15:26 UTC
-
New Dual-Action antibody shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called MCLA-129 in people with advanced lung, stomach, esophageal, head and neck, or colorectal cancers that have not responded to standard treatments. The drug is a bispecific antibody designed to attach to two cancer-related targets (EGFR a…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated May 01, 2026 15:25 UTC
-
New drug duo aims to shrink head and neck tumors
Disease control OngoingThis study tests two different schedules of the experimental drug FID-007 combined with cetuximab in 46 adults with advanced head and neck cancer that has returned or spread. The goal is to see if the combo can shrink tumors and how safe it is. Participants must have already trie…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Fulgent Pharma LLC. • Aim: Disease control
Last updated May 01, 2026 15:24 UTC
-
New combo therapy targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 120 people with various canc…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: NeoTX Therapeutics Ltd. • Aim: Disease control
Last updated May 01, 2026 15:24 UTC
-
New three-step combo therapy targets tough head and neck cancers
Disease control OngoingThis study tests a three-step treatment plan for people with a type of head and neck cancer not linked to HPV. First, patients receive a drug called palbociclib before standard chemoradiation, then they get more palbociclib after treatment. The goal is to see if this approach hel…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New combo therapy aims to shrink head and neck tumors in first-line treatment
Disease control OngoingThis study tests whether a drug called tislelizumab, alone or with other experimental drugs, can shrink or control tumors in people with advanced head and neck cancer that has come back or spread. About 160 adults whose cancer cannot be cured by local treatments will receive thes…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
New combo therapy aims to shrink head and neck tumors
Disease control OngoingThis study tests whether adding an experimental drug (domvanalimab) to a standard immunotherapy (zimberelimab) plus chemotherapy works better than the standard immunotherapy plus chemotherapy alone for people with head and neck cancer that has spread or come back. About 100 adult…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
Immunotherapy may replace chemo in head and neck cancer treatment
Disease control OngoingThis study compares two treatments for people with advanced p16-positive head and neck cancer. One group gets radiation plus the immunotherapy drug pembrolizumab (Keytruda), while the other gets radiation plus standard chemotherapy. The goal is to see if the immunotherapy approac…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Loren Mell, MD • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
HPV vaccine combo shows promise against head and neck cancer
Disease control OngoingThis study tests whether combining an HPV DNA vaccine with immune-boosting drugs can shrink advanced head and neck cancers caused by HPV types 16 or 18. About 56 adults with resectable tumors will receive the treatment before surgery. The main goal is to see if the tumor has fewe…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
Could a diabetes drug help fight head and neck cancer?
Disease control OngoingThis study tests whether adding the diabetes drug metformin to the immunotherapy drug pembrolizumab can help shrink tumors in people with advanced head and neck cancer that has spread or come back. The goal is to see if this combination can boost the body's natural killer cells t…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Trisha Wise-Draper • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tested a new drug called sEphB4-HSA combined with standard chemotherapy in 61 people with advanced or metastatic solid tumors (like head and neck, pancreatic, lung, and gallbladder cancers). The goal was to find the best dose and check for side effects. Res…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
Immunotherapy plus chemo shows promise against tough head and neck cancers
Disease control OngoingThis study tests whether adding an immunotherapy drug (treprizumab) to standard chemotherapy before surgery can improve outcomes for people with advanced head and neck cancer. About 122 participants will be randomly assigned to receive either the combination or chemotherapy alone…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
New antibody IMT-009 enters human trials for Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug called IMT-009 in about 67 people with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goals are to find a safe dose, understand side effects, and see if the drug can shrink tumors. The study is o…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Immunitas Therapeutics • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New combo therapy aims to extend life without harming quality of life in head and neck cancer
Disease control OngoingThis study compares two treatments for head and neck cancer that has spread to 1-3 other body sites. One group gets targeted radiation alone, the other gets radiation plus chemotherapy. The goal is to see which approach helps people live longer with good quality of life and fewer…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Groupe Oncologie Radiotherapie Tete et Cou • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New drug combo offers hope for hard-to-treat head and neck cancer
Disease control OngoingThis study tests a new drug called SI-B001 combined with paclitaxel in people with head and neck cancer that has come back or spread. It is for patients whose cancer worsened after standard treatments like immunotherapy or chemotherapy. The goal is to see if the combination shrin…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New combo therapy shows promise for Drug-Resistant cancers
Disease control OngoingThis study tests a combination of three treatments (IL-2 injections, targeted radiation, and the immunotherapy drug pembrolizumab) in adults with advanced lung, skin, kidney, or head and neck cancers that no longer respond to standard immunotherapy. The goal is to see if this tri…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Megan Daly, MD • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New cocktail shows promise for tough head and neck cancers
Disease control OngoingThis study tested a combination of three drugs (cisplatin, nab-paclitaxel, and cetuximab) in 74 people with head and neck cancer that cannot be cured. The goal was to see how well the treatment controls the disease and what side effects occur. The approach is for disease manageme…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New drug combo aims to stop head and neck cancer recurrence
Disease control OngoingThis study tests whether adding lenvatinib to pembrolizumab (immunotherapy) after standard chemoradiation can help prevent head and neck cancer from coming back. About 50 adults with advanced, PD-L1 positive cancer will receive either the combination or pembrolizumab alone as mai…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Universität des Saarlandes • Aim: Disease control
Last updated Apr 29, 2026 15:15 UTC
-
Experimental vaccine combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase study tested a new cancer vaccine (p53MVA) combined with the immunotherapy drug pembrolizumab in 11 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to see if the combination is safe and can help the immune system re…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC
-
Triple threat: vaccine, immunotherapy, and chemo join forces against HPV-Linked cancer
Disease control OngoingThis study is for people with a type of head and neck cancer caused by HPV-16 that is considered intermediate risk. The goal is to see if adding an HPV vaccine (ISA101b) and an immunotherapy drug (pembrolizumab) to standard chemoradiation can help keep the cancer from coming back…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC
-
New combo therapy shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether adding the drug ipatasertib to standard immunotherapy (pembrolizumab) can help control recurrent or metastatic head and neck cancer better than immunotherapy alone. About 52 adults with incurable squamous cell carcinoma of the head and neck will take part…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new medicine, PF-08046032, alone and with another drug (sasanlimab) in adults with advanced lymphomas or solid tumors that have spread or not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the c…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC
-
New combo therapy aims to shrink tough tumors
Disease control OngoingThis study tests a new drug (ARRY-614) combined with standard immunotherapies (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors like lung, kidney, skin, and head/neck cancers. The first part finds a safe dose, and the second part checks if the combinat…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC
-
New combo therapy aims to shrink head and neck tumors
Disease control OngoingThis study tests a new drug called NT219 combined with either pembrolizumab or cetuximab in people with head and neck cancer that has come back or spread. The goal is to see if the combination can shrink tumors. About 29 adults with incurable head and neck squamous cell carcinoma…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC
-
New hope for head and neck cancer patients who failed standard therapy
Disease control OngoingThis study tests a new drug called SI-B001 in 11 adults with advanced head and neck cancer that has returned or spread and no longer responds to standard treatments like immunotherapy or chemotherapy. The goal is to see if the drug can shrink tumors and how safe it is. Participan…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC
-
New combo therapy before surgery shows promise for tough head and neck cancers
Disease control OngoingThis study tests giving a short course of targeted radiation plus an immunotherapy drug (pembrolizumab) before surgery for people with advanced head and neck cancer that is not caused by HPV. The goal is to shrink or eliminate the tumor before surgery, and to see if this approach…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC
-
Which Follow-Up schedule saves more lives after head and neck cancer?
Knowledge-focused OngoingThis study compares two different follow-up strategies for people who have finished treatment for head and neck cancer. The goal is to see if a more intensive follow-up schedule helps people live longer than a standard one. Participants are smokers or heavy drinkers over age 35 w…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:51 UTC